Aptose Biosciences (APTO) Stock Price, News & Analysis

Company Overview

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Key Stats

• Today's Range: N/A
• 50-Day Range: $1.71 to $6.86
• 52-Week Range: N/A
• Volume: 650,294 shs
• Average Volume: 227,964 shs
• Market Capitalization: $3.66 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Strong Buy

APTO Stock Analysis - Frequently Asked Questions

How were Aptose Biosciences' earnings last quarter?

Aptose Biosciences Inc. (NASDAQ:APTO) released its earnings results on Thursday, August, 8th. The biotechnology company reported ($12.90) earnings per share for the quarter, beating analysts' consensus estimates of ($17.40) by $4.50.

When did Aptose Biosciences' stock split?

Shares of Aptose Biosciences reverse split on the morning of Wednesday, February 26th 2025.The 1-30 reverse split was announced on Tuesday, February 18th 2025. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 25th 2025. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aptose Biosciences investors own include Digital Turbine (APPS), Okta (OKTA), Canoo (GOEV), CrowdStrike (CRWD) and NVIDIA (NVDA).

Company Calendar

• Last Earnings: 8/08/2024
• Today: 10/15/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:APTO
• CIK: 882361
• Web: www.aptose.com
• Phone: 858-926-2730
• Fax: 905-234-2120
• Employees: 31
• Year Founded: 2014

Price Target and Rating

• Average Price Target for Aptose Biosciences: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($89.19)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$51.21 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -5,683.22%
• Return on Assets: -300.44%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.05
• Quick Ratio: 1.05

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.19) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 2,141,000
• Free Float: 63,446,000
• Market Cap: $3.66 million
• Optionable: No Data
• Beta: 1.04